Pharmacological MRI of stem cell transplants in the 3-nitroproprionic acid-damaged striatum

Neuroscience

Volumn 144, Issue 1, 2007, Pages 100-109

  Roberts, T J ^a   Price, J ^a   Williams, S C R ^a   Modo, M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

bromocriptine; cell transplant; Huntington's disease; negative BOLD; phMRI; stem cell

Indexed keywords

3 NITROPROPIONIC ACID; BROMOCRIPTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DAMAGE; CELL ACTIVITY; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; LOCOMOTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PHARMACOLOGICAL NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION;

ANIMALS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; BODY TEMPERATURE; BROMOCRIPTINE; CEREBRAL CORTEX; DATA INTERPRETATION, STATISTICAL; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MAGNETIC RESONANCE IMAGING; MOTOR ACTIVITY; NEOSTRIATUM; NITRO COMPOUNDS; OXYGEN; PROPIONIC ACIDS; RATS; RATS, INBRED LEW; RESPIRATORY MECHANICS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEREOTYPED BEHAVIOR;

EID: 33751534426     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.09.015     Document Type: Article

References (35)

1. Bachoud-Lévi A.-C., Remy P., Nguyen J., BrugiŠres P., Lefaucheur J.-P., Bourdet C., Baudic S., Gaura V., Maison P., Haddad B., Boiss M.-F., Grandmougin T., Jeny R., Bartolomeo P., Dalla Barba G., Degos J.-D., Lisovoski F., Ergis A.-M., Palihous E., Cesaro P., Hantraye P., and Peschanski M. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation. Lancet 356 (2000) 1975-1979
2. Borsook D., Becerra L., and Hargreaves R. A role for fMRI in optimizing CNS drug development. Nat Rev Drug Discov 5 (2006) 411-425
3. Calon F., Hadj Tahar A., Blanchet P.J., Morissette M., Grondin R., Goulet M., Doucet J.P., Robertson G.S., Nestler E., Di Paolo T., and Bedard P.J. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci 23 (2000) S92-S100
4. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., Keltner J.R., Beal M.F., Rosen B.R., and Jenkins B.G. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38 (1997) 389-398
5. Chen Y.C., Mandeville J.B., Nguyen T.V., Talele A., Cavagna F., and Jenkins B.G. Improved mapping of pharmacologically induced neuronal activation using the IRON technique with superparamagnetic blood pool agents. J Magn Reson Imaging 14 (2001) 517-524
6. Chen Y.I., Brownell A.-L., Galpern W., Isacson O., Bogdanov M., Beal M.F., Livni E., Rosen B.R., and Jenkins B.G. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET, and behavioral assessment. Neuroreport 10 (1999) 2881-2886
7. Chen Y.I., Choi J.K., and Jenkins B.G. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse 55 (2005) 80-88
8. Choi J.K., Chen Y.I., Hamel E., and Jenkins B.G. Brain hemodynamic changes mediated by dopamine receptors: Role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. Neuroimage 30 (2006) 700-712
9. Chyi T., and Chang C. Temporal evolution of 3-nitroproprionic acid-induced neurodegeneration in the rat brain by T2-weighted, diffusion-weighted, and perfusion magnetic resonance imaging. Neuroscience 92 (1999) 1035-1041
10. De Keyser J., De Backer J.P., Wilczak N., and Herroelen L. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 1147-1154
11. Eilam D., and Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. Eur J Pharmacol 161 (1989) 151-157
12. Ginovart N., Lundin A., Farde L., Halldin C., Backman L., Swahn C.G., Pauli S., and Sedvall G. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120 Pt 3 (1997) 503-514
13. Hagino H., Tabuchi E., Kurachi M., Saitoh O., Sun Y., Kondoh T., Ono T., and Torii K. Effects of D2 dopamine receptor agonist and antagonist on brain activity in the rat assessed by functional magnetic resonance imaging. Brain Res 813 (1998) 367-373
14. Hodges H., Watts H., and Reuter I. Stem cells: prospects for functional repair of brain damage. Transplant Proc 35 (2003) 1250-1255
15. Hoffman D.C., and Wise R.A. Locomotor-activating effects of the D2 agonist bromocriptine show environment-specific sensitization following repeated injections. Psychopharmacology (Berl) 107 (1992) 277-284
16. Honey G., and Bullmore E.T. Human pharmacological MRI. Trends Pharmacol Sci 25 (2004) 366-374
17. Ireland MD, Lowe AS, Beech JS, Williams SCR (2002) Groups statistical parametric maps of rat forepaw stimulation using single and multiple echo data. Proceedings of the International Society for Magnetic Resonance in Medicine. Proceedings of the ISMRM-ESMRMB Joint Annual Meeting, Hawaii, 3:1356.
18. Ireland M.D., Lowe A.S., Reavill C., James M.F., Leslie R.A., and Williams S.C. Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging. Neuroscience 133 (2005) 315-326
19. Jenkins B.G., Chen Y.C.I., and Mandeville J.B. Pharmacological magnetic resonance imaging (phMRI). In: van Bruggen N., and Roberts T. (Eds). Biomedical imaging in experimental neuroscience (2003), CRC Press, Boca Raton, FL 155-209
20. Jenkins B.G., Sanchez-Pernaute R., Brownell A.L., Chen Y.C., and Isacson O. Mapping dopamine function in primates using pharmacologic magnetic resonance imaging. J Neurosci 24 (2004) 9553-9560
21. Kimberg D.Y., Aguirre G.K., Lease J., and D'Esposito M. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Hum Brain Mapp 12 (2001) 246-257
22. Lee W.-T., and Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitroproprionic acid-induced brain lesions: An animal model of Huntington's disease. Prog Neurobiol 72 (2004) 87-110
23. Leslie R.A., and James M.F. Pharmacological magnetic resonance imaging: A new application for functional MRI. Trends Pharmacol Sci 21 (2000) 314-318
24. Modo M., Rezaie P., Heuschling P., Patel S., Male D.K., and Hodges H. Transplantation of neural stem cells in a rat model of stroke: assessment of short-term graft survival and acute host immunological response. Brain Res 958 (2002) 70-82
25. Modo M., Roberts T.J., Sandhu J.K., and Williams S.C.R. In vivo monitoring of cellular transplants by magnetic resonance imaging and positron emission tomography. Expert Opin Biol Ther 4 (2004) 145-155
26. Nishi A., Snyder G.L., and Greengard P. Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J Neurosci 17 (1997) 8147-8155
27. Ouary S., Bizat N., Altairac S., Menetrat H., Mittoux V., Conde F., Hantraye P., and Brouillet E. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitroproprionic acid in rats: implications for neuroprotection studies. Neuroscience 97 (2000) 521-530
28. Pavese N., Andrews T.C., Brooks D.J., Ho A.K., Rosser A.E., Barker R.A., Robbins T.W., Sahakian B.J., Dunnett S.B., and Piccini P. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 126 (2003) 1127-1135
29. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997), Academic Press, San Diego
30. Roberts T.J., Price J., Williams S.C., and Modo M. Preservation of striatal tissue and behavioral function after neural stem cell transplantation in a rat model of Huntington's disease. Neuroscience 139 (2006) 1187-1199
31. Sinden J.D., Rashid-Doubell F., Kershaw T.R., Nelson A., Chadwick A., Jat P.S., Noble M.D., Hodges H., and Gray J.A. Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampus. Neuroscience 81 (1997) 599-608
32. Sun Z., Xie J., and Reiner A. The differential vulnerability of striatal projection neurons in 3-nitroproprionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp Neurol 176 (2002) 55-65
33. Ugurbil K., Adriany G., Andersen P., Chen W., Gruetter R., Hu X., Merkle H., Kim D.S., Kim S.G., Strupp J., Zhu X.H., and Ogawa S. Magnetic resonance studies of brain function and neurochemistry. Annu Rev Biomed Eng 2 (2000) 633-660
34. van Oostrom J.C., Maguire R.P., Verschuuren-Bemelmans C.C., Veenma-van der Duin L., Pruim J., Roos R.A., and Leenders K.L. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease. Neurology 65 (2005) 941-943
35. Wilkinson D., and Halligan P. The relevance of behavioural measures for functional-imaging studies of cognition. Nat Rev Neurosci 5 (2004) 67-73